VASOSTRICT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vasostrict, and when can generic versions of Vasostrict launch?
Vasostrict is a drug marketed by Ph Health and is included in one NDA. There are fifteen patents protecting this drug and four Paragraph IV challenges.
The generic ingredient in VASOSTRICT is vasopressin. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vasostrict
A generic version of VASOSTRICT was approved as vasopressin by AM REGENT on August 3rd, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VASOSTRICT?
- What are the global sales for VASOSTRICT?
- What is Average Wholesale Price for VASOSTRICT?
Summary for VASOSTRICT
| US Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VASOSTRICT |
Paragraph IV (Patent) Challenges for VASOSTRICT
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VASOSTRICT | Injection | vasopressin | 20 units/100 mL | 204485 | 1 | 2022-12-20 |
| VASOSTRICT | Injection | vasopressin | 40 units/100 mL and 60 units/100 mL | 204485 | 1 | 2022-02-28 |
| VASOSTRICT | Injection | vasopressin | 200 units/10 mL | 204485 | 1 | 2018-06-29 |
| VASOSTRICT | Injection | vasopressin | 20 units/mL, 1 mL | 204485 | 1 | 2018-03-23 |
US Patents and Regulatory Information for VASOSTRICT
VASOSTRICT is protected by fifteen US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-004 | Apr 15, 2020 | DISCN | Yes | No | 12,186,362 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-006 | Apr 12, 2023 | DISCN | Yes | No | 9,919,026 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-002 | Dec 17, 2016 | AP | RX | Yes | Yes | 9,744,209 | ⤷ Start Trial | ⤷ Start Trial | |||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-006 | Apr 12, 2023 | DISCN | Yes | No | 9,925,233 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-004 | Apr 15, 2020 | DISCN | Yes | No | 9,925,233 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-006 | Apr 12, 2023 | DISCN | Yes | No | 9,925,234 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
